Identification of candidate genes for lung cancer somatic mutation test kits

被引:18
作者
Chen, Yong [1 ]
Shi, Jian-Xin [1 ]
Pan, Xu-Feng [1 ]
Feng, Jian [1 ]
Zhao, Heng [1 ]
机构
[1] Shanghai Chest Hosp, Thorac Dept, Shanghai 200030, Peoples R China
关键词
Lung cancer; Next-generation sequencing; Somatic mutation kit; COSMIC; RECEPTOR TYROSINE KINASE; PHASE-II TRIAL; GEFITINIB; EGFR; RESISTANCE; INHIBITORS; ERLOTINIB; THERAPY; CATALOG;
D O I
10.1590/S1415-47572013000300022
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Over the past three decades, mortality from lung cancer has sharply and continuously increased in China, ascending to the first cause of death among all types of cancer. The ability to identify the actual sequence of gene mutations may help doctors determine which mutations lead to precancerous lesions and which produce invasive carcinomas, especially using next-generation sequencing (NGS) technology. In this study, we analyzed the latest lung cancer data in the COSMIC database, in order to find genomic "hotspots" that are frequently mutated in human lung cancer genomes. The results revealed that the most frequently mutated lung cancer genes are EGFR, KRAS and TP53. In recent years, EGFR and KRAS lung cancer test kits have been utilized for detecting lung cancer patients, but they presented many disadvantages, as they proved to be of low sensitivity, labor-intensive and time-consuming. In this study, we constructed a more complete catalogue of lung cancer mutation events including 145 mutated genes. With the genes of this list it may be feasible to develop a NGS kit for lung cancer mutation detection.
引用
收藏
页码:455 / 464
页数:10
相关论文
共 27 条
[1]   The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website [J].
Bamford, S ;
Dawson, E ;
Forbes, S ;
Clements, J ;
Pettett, R ;
Dogan, A ;
Flanagan, A ;
Teague, J ;
Futreal, PA ;
Stratton, MR ;
Wooster, R .
BRITISH JOURNAL OF CANCER, 2004, 91 (02) :355-358
[2]  
Brose MS, 2002, CANCER RES, V62, P6997
[3]   Novel targets for lung cancer therapy: Part II [J].
Dy, GK ;
Adjei, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (13) :3016-3028
[4]   Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers [J].
Engelman, Jeffrey A. ;
Chen, Liang ;
Tan, Xiaohong ;
Crosby, Katherine ;
Guimaraes, Alexander R. ;
Upadhyay, Rabi ;
Maira, Michel ;
McNamara, Kate ;
Perera, Samanthi A. ;
Song, Youngchul ;
Chirieac, Lucian R. ;
Kaur, Ramneet ;
Lightbown, Angela ;
Simendinger, Jessica ;
Li, Timothy ;
Padera, Robert F. ;
Garcia-Echeverria, Carlos ;
Weissleder, Ralph ;
Mahmood, Umar ;
Cantley, Lewis C. ;
Wong, Kwok-Kin .
NATURE MEDICINE, 2008, 14 (12) :1351-1356
[5]   COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer [J].
Forbes, Simon A. ;
Bindal, Nidhi ;
Bamford, Sally ;
Cole, Charlotte ;
Kok, Chai Yin ;
Beare, David ;
Jia, Mingming ;
Shepherd, Rebecca ;
Leung, Kenric ;
Menzies, Andrew ;
Teague, Jon W. ;
Campbell, Peter J. ;
Stratton, Michael R. ;
Futreal, P. Andrew .
NUCLEIC ACIDS RESEARCH, 2011, 39 :D945-D950
[6]   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].
Fukuoka, M ;
Yano, S ;
Giaccone, G ;
Tamura, T ;
Nakagawa, K ;
Douillard, JY ;
Nishiwaki, Y ;
Vansteenkiste, J ;
Kudoh, S ;
Rischin, D ;
Eek, R ;
Horai, T ;
Noda, K ;
Takata, I ;
Smit, E ;
Averbuch, S ;
Macleod, A ;
Feyereislova, A ;
Dong, RP ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246
[7]   Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1 [J].
Giaccone, G ;
Herbst, RS ;
Manegold, C ;
Scagliotti, G ;
Rosell, R ;
Miller, V ;
Natale, RB ;
Schiller, JH ;
von Pawel, J ;
Pluzanska, A ;
Gatzemeier, M ;
Grous, J ;
Ochs, JS ;
Averbuch, SD ;
Wolf, MK ;
Rennie, P ;
Fandi, A ;
Johnson, DH .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :777-784
[8]   BioMart Central Portal-unified access to biological data [J].
Haider, Syed ;
Ballester, Benoit ;
Smedley, Damian ;
Zhang, Junjun ;
Rice, Peter ;
Kasprzyk, Arek .
NUCLEIC ACIDS RESEARCH, 2009, 37 :W23-W27
[9]   K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer:: a combined analysis of 881 cases [J].
Huncharek, M ;
Muscat, J ;
Geschwind, JF .
CARCINOGENESIS, 1999, 20 (08) :1507-1510
[10]   Global Patterns of Cancer Incidence and Mortality Rates and Trends [J].
Jemal, Ahmedin ;
Center, Melissa M. ;
DeSantis, Carol ;
Ward, Elizabeth M. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (08) :1893-1907